Square Pharmaceuticals PLC. announcements
313 Dhaka Stock Exchange announcements for Square Pharmaceuticals PLC. (SQURPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2010 (17).
- (continuation of news of SQURPHARMA ): Again, as per un-audited half yearly accounts as on 30.06.10 (April' 10 to Sep' 1
(continuation of news of SQURPHARMA ): Again, as per un-audited half yearly accounts as on 30.06.10 (April' 10 to Sep' 10), the company has also reported net profit after tax of the company was Tk. 1,498.81 million with EPS of Tk. 76.40 as against Tk. 1,280.21 million and Tk. 65.26 (restated) respectively for the same period of the previous year. Whereas net profit after tax was Tk. 776.72 million with EPS of Tk. 39.59 for the period of 3 months (July' 10 to Sep' 10) ended on 30.09.10 as against Tk. 690.60 million and Tk. 35.20 (restated) respectively for the same period of the previous year.
The first part of this announcement is missing from the archive. - (H/Y): As per un-audited half yearly accounts as on 30.09.10 (April' 10 to Sep' 10), the company has reported consolidat
(H/Y): As per un-audited half yearly accounts as on 30.09.10 (April' 10 to Sep' 10), the company has reported consolidated net profit after tax and minority interest was Tk. 1,810.39 million with consolidated EPS of Tk. 92.28 as against Tk. 1,390.92 million and Tk. 70.90 (restated) respectively for the same period of the previous year. Whereas consolidated profit after tax and minority interest was Tk. 903.58 million with consolidated EPS of Tk. 46.06 for the period of 3 months (July' 10 to Sep' 10) ended on 30.09.10 as against Tk. 720.91 million and Tk. 36.75 (restated) respectively for the same period of the previous year. (continue)
- Ms. Jahanara Chowdhury, one of the Sponsors/Directors of the company, has further reported that she has completed her sa
Ms. Jahanara Chowdhury, one of the Sponsors/Directors of the company, has further reported that she has completed her sale of 2,000 shares of the company at prevailing market price through Stock Exchange as announced earlier.
- The Company has informed that it has credited the Stock Dividend for the year 2009-2010 to the respective shareholders'
The Company has informed that it has credited the Stock Dividend for the year 2009-2010 to the respective shareholders' BO Accounts on 30.09.10.
- Ms. Jahanara Chowdhury, one of the Sponsors/Directors of the company, has reported her intention to sell 2,000 shares ou
Ms. Jahanara Chowdhury, one of the Sponsors/Directors of the company, has reported her intention to sell 2,000 shares out of her total holdings of 91,352 shares of the company at prevailing market price through Stock Exchange within next 30 working days.
- In response to a DSE query, the company has informed that there is no undisclosed price sensitive information of the com
In response to a DSE query, the company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike.
- Normal trading of the shares of the company will resume on 29.08.10 after record date.
Normal trading of the shares of the company will resume on 29.08.10 after record date.
- Trading of the shares of the company will remain suspended on record date i.e. 26.08.10.
Trading of the shares of the company will remain suspended on record date i.e. 26.08.10.
- Trading of the shares of the company will be allowed only in the Spot Market and Block/Odd lot transactions will also be
Trading of the shares of the company will be allowed only in the Spot Market and Block/Odd lot transactions will also be settled as per Spot settlement cycle with cum benefit from 23.08.10 to 25.08.10. Trading of the shares of the company will remain suspended on record date i.e. 26.08.10.
- As per un-audited quarterly accounts for the 1st quarter ended on 30th June 2010 (April'10 to June'10), the company has
As per un-audited quarterly accounts for the 1st quarter ended on 30th June 2010 (April'10 to June'10), the company has reported net profit after tax of Tk. 722.09 million with basic EPS of Tk. 47.85 as against Tk. 589.61 million and Tk. 39.07 (restated) respectively for the same period of the previous year. However, considering proposed bonus share @ 30% for the year 2009-10, diluted EPS will be Tk. 36.81 as on 30.06.10 and Tk. 30.06 (restated) as on 30.06.09.
- There will be no price limit on the trading of the shares of the company today (18.07.10) following its corporate declar
There will be no price limit on the trading of the shares of the company today (18.07.10) following its corporate declaration.
- The Board of Directors has recommended cash dividend @ 35% and stock dividend @ 30% for the year ended March 31, 2010. D
The Board of Directors has recommended cash dividend @ 35% and stock dividend @ 30% for the year ended March 31, 2010. Date of AGM: 21.09.10, Time: 10:30 AM, Venue: Factory premises, Kaliakoir, Gazipur. Record Date: 26.08.10. The company has also reported Net Asset Value (NAV) of Tk. 11,554.38 million, Earnings Per Share (EPS) of Tk. 138.36 and Net Operating Cash Flow per share of Tk. 176.51 for the year ended on March 31, 2010.
- As per Regulation 30 of DSE Listing Regulations, the company has informed that a meeting of the Board of Directors of th
As per Regulation 30 of DSE Listing Regulations, the company has informed that a meeting of the Board of Directors of the company will be held on 15.07.10 at 4:00 PM to consider, among others, audited financial statements of the company for the year ended 31st March, 2010.
- The company has informed that the Board of Directors of the company has approved an agreement with M/s R.A.K. Pharmaceut
The company has informed that the Board of Directors of the company has approved an agreement with M/s R.A.K. Pharmaceuticals Pvt. Ltd. for toll manufacturing of three products on behalf of Square Pharmaceuticals Ltd. to meet the increasing demand of those Square's products.
- The company has informed that Medicines and Healthcare Products Regulatory Agency (MHRA) of UK has renewed Square Pharma
The company has informed that Medicines and Healthcare Products Regulatory Agency (MHRA) of UK has renewed Square Pharmaceuticals' GMP (Good Manufacturing Practice) compliance certificate for next 3 years. In 2007 Square achieved this certification as a first Bangladeshi company and since then it is exporting its products to UK. This year the company is expecting to complete export formalities of 14 more products for UK.
- As per un-audited quarterly accounts for the 3rd quarter ended on 31st December 2009 (April to December), the Company ha
As per un-audited quarterly accounts for the 3rd quarter ended on 31st December 2009 (April to December), the Company has reported net profit after tax of Tk. 1,749.61 m. with EPS of Tk. 115.94 as against Tk. 1,551.40 m. and Tk. 102.81 respectively for the same period of the previous year.
- In response to a DSE query, the company has informed that there is no undisclosed price sensitive information of the com
In response to a DSE query, the company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.